Genprex published lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month.
Genprex will present in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT.
Additional research is being done in the field that validates non-viral vector delivery as the next evolution in gene therapy.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's webcast presentation.
Independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC).
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's presentation on September 9, 2019 in New York City.
These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found at Genprex.com.
Genprex's Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference in New York City on September 4, 2019.
Company’s recent performance sets path for future milestones, commercialization
Genprex's newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.